INmune Bio publishes Phase 2 Alzheimer's trial results in peer-reviewed journal
Tweet Send to a Friend
INmune Bio Inc. (NASDAQ: INMB) announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
